DOCSLIB.ORG

Specialty Drugs Requiring Precertification

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Specialty Drugs Requiring Precertification Specialty Drugs Requiring Precertification Policy Number: Original Effective Date: MM.04.009 09/01/2008 Line(s) of Business: Current Effective Date: HMO; PPO; QUEST Integration 06/27/2014 Section: Prescription Drugs Place(s) of Service: Home; Office; Outpatient; Ambulatory Infusion Suite I. Description A specialty drug is a drug that is typically high in cost (greater than $600 per month) and has one or more of the following characteristics: Specialized patient training on the administration of the drug (including supplies and devices needed for administration) is required. Coordination of care is required prior to drug therapy initiation and/or during therapy. Unique patient compliance and safety monitoring requirements. Unique requirements for handling, shipping and storage. Restricted access or limited distribution. The intent of this policy is to require precertification of designated specialty drugs on the date of approval by the Food and Drug Administration (FDA). This policy applies to drugs covered under the medical benefit and under the prescription drug rider benefit. II. Criteria/Guidelines A. Precertification is required for specialty drugs, effective on the date of approval by the FDA. Refer to Appendices A and B for the lists of drugs requiring precertification. B. A specialty drug is covered (subject to Limitations/Exclusions and Administrative Guidelines) when the following criteria are met: 1. It is prescribed for an FDA approved indication. a. Its use is consistent with the manufacturer’s prescribing information. b. When the FDA-approved indication lacks patient selection specificity, the patient meets the eligibility criteria for the clinical study or studies upon which the FDA approval was based. 2. When a specialty drug is requested for an off-label indication, HMSA’s Off-Label Drug Use policy criteria must be met. Specialty Drugs Requiring Precertification 2 III. Limitations/Exclusions A. When a request for a specialty drug is approved, coverage is based on a trial of therapy concept. The drug will be approved for a specified period during which the patient’s response to therapy will be assessed. Specific measurable response(s) should be identified and documented at the time of initial approval. Continuation of the drug is covered if the patient demonstrates a measurable response. B. This policy does not apply to specialty drugs with an existing policy. If there is an existing policy, coverage will be based on policy criteria. Refer to Appendices C and D for the lists of drugs requiring precertification for which there is a medical policy. C. If there is an existing policy for a drug in the same therapeutic class, coverage will be based on the policy criteria. IV. Administrative Guidelines A. Precertification is required for specialty drugs, effective on the date of approval by the FDA. At the time precertification is being requested, please refer to Appendices A and B for the lists of drugs requiring precertification in accordance with criteria stated in this policy. To precertify, please complete HMSA’s Drug Review Request or the CVS Drug Review Request. For requests submitted to HMSA, include the following documentation: 1. Clinical information supporting the diagnosis. 2. Proposed treatment plan. B. Specialty drugs listed in Appendices A and B will be reviewed on a regular basis and a determination will be made regarding continuation of the precertification requirement and/or development of a policy. Specialty Drugs Requiring Precertification 3 V. Appendices APPENDIX A Drugs requiring precertification from HMSA in accordance with criteria stated in this policy: Brand/Generic Name Route of HCPCS Code Precertification Administration Effective Date Acthar gel (Corticotropin) IM/SQ J0800 September 1, 2012 Arcalyst (Rilonacept) IM/SQ J2793 January 1, 2010 Benlysta (Belimumab) IV J0490 November 1, 2011 Berinert (C1 Esterase Inhibitor) IV J0597 December 1, 2010 Bexxar (Tositumomab) IV A9545 June 1, 2009 Cerezyme (Imiglucerase) IV J1786 October 1, 2014 Cinryze (Human C1 Esterase Inhibitor) IV J0598 July 1, 2009 Cosentyx (secukinumab) SQ J3490/J3590 February 13, 2015 Cyramza (Ramucirumab) IV J3490/J3590 April 23, 2014 Elelyso (Taliglucerase alfa) IV J3060 February 1, 2013 Entyvio (vedolizumab) IV J3490/J3590 June 12, 2014 Eylea (Aflibercept) for off-label Intravitreous J0178 August 1, 2012 indications Firazyr (Icatibant) SQ J1744 February 1, 2012 Folotyn (Pralatrexate) IV J9307 May 1, 2010 Gattex (Teduglutide) SQ J3490/J3590 December 1, 2013 Gazyva (Obinutuzumab) IV J9301 May 1, 2014 Ilaris (Canakinumab) SQ J0638 December 1, 2009 Iluvien (fluocinolone acetonide Intravitreous J3490/J3590 February 13, 2015 intravitreal implant) Jetrea (Ocriplasmin) for off-label Intravitreous J7316 June 1, 2013 indications Kadcyla (Trastuzumab emtansine) IV J9354 August 1, 2013 Kalbitor (Ecallantide) SQ J1290 June 1, 2011 Keytruda (pembrolizumab) IV J3490/J3590 September 18, 2014 Specialty Drugs Requiring Precertification 4 Krystexxa (Pegloticase) IV J2507 September 1, 2012 Kynamro (Mipomersen sodium) SQ J3490/J3590 June 1, 2013 Kyprolis (Carfilzomib) IV J9047 February 1, 2013 Lanreotide (Somatuline Depot) SQ J1930 June 1, 2013 Lucentis (Ranibizumab) for off-label Intravitreous J2778 December 1, 2010 indications Macugen (Pegaptanib) for off-label Intravitreous J2503 December 1, 2010 indications Myalept (Metreleptin) SQ J3490/J3590 March 27, 2014 Nplate (Romiplostim) SQ J2796 June 1, 2009 Opdivo (nivolumab) IV J9999 March 16, 2015 Perjeta (Pertuzumab) IV J9306 November 1, 2012 Praluent (alirocumab) Injection J3490/J3590 June 10, 2015 Prolia (Denosumab) for off-label SQ J0897 September 1, 2010 indications Provenge (Sipuleucel T) IV Q2043 September 1, 2010 Repatha (evolucumab) Injection J3490/J3590 June 10, 2015 Rituxan (Rituximab) for non-RA and IV J9310 November 1, 2009 non-oncologic indications Ruconest (recombinant human C1 IV J3490/J3590 September 05, 2014 esterase inhibitor) Signifor (Pasireotide diaspartate) SQ J3490/J3590 June 1, 2013 Soliris (Eculizumab) IV J1300 May 1, 2009 Sylvant (siltuximab) IV J3490/J3590 May 1, 2014 Synribo (Omacetaxine mepesuccinate) SQ J9262 June 1, 2013 Torisel (Temsirolimus) IV J9330 Now in Effect Vimizim (Elosulfase alfa) IV J1322 March 27, 2014 Unituxin (dinutuximab) Injection J3490/J3590 August 21, 2015 VPRIV (Veleglucerase) IV J3385 October 1, 2014 Xgeva (Denosumab) for off-label SQ J0897 September 1, 2011 indications Xofigo (Radium Ra 223 Dichloride) IV A9606 December 1, 2013 Yervoy (Ipilimumab) IV J9228 September 1, 2011 Zaltrap (Ziv-aflibercept) IV J9400 January 1, 2013 Specialty Drugs Requiring Precertification 5 APPENDIX B Drugs requiring precertification from CVS in accordance with criteria stated in this policy: Brand/Generic Name Route of Administration Precertification Effective Date Aubagio (teriflunomide) Oral 08/01/2014 Bosulif (Bosutinib monohydrate ) Oral 08/01/2014 Buphenyl (sodium phenylbutyrate) Oral 08/01/2014 Cerdelga (eliglustat) Oral 09/05/2014 Cometriq (cabozantinib) Oral 08/01/2014 Esbriet (pirfenidone) Oral 10/29/2014 Farydak (panobinostat) Oral 02/23/2015 Gilotrif (afatinib) Oral 10/01/2014 Hetlioz (tasimelteon) Oral 03/27/2014 Iclusig (ponatinib) Oral 01/01/2014 Imbruvica (Ibrutinib) Oral 08/01/2014 Inlyta (axitinib) Oral 08/01/2014 Juxtapid (lomitapide) Oral 12/21/2012 Kitabis Pak (tobramycin) Inhaled 12/02/2014 Mekinist (trametinib) Oral 08/01/2014 Northera (droxidopa) Oral 03/27/2014 Ofev (nintedanib) Oral 10/29/2014 Olysio (simeprevir) Oral 06/01/2014 Opsumit (macitentan) Oral 08/01/2014 Orkambi (lumacaftor/ivacaftor) Oral 07/02/2015 Orenitram (treprostinil) Oral 10/01/2014 Otezla (apremilast) Oral 04/03/2014 Pomalyst (pomalidomide) Oral 08/01/2014 Procysbi (Cysteamine Bitartrate) Oral 08/01/2014 Ravicti (glycerol phenylbutyrate) Oral 08/01/2014 Specialty Drugs Requiring Precertification 6 Stivarga (regorafenib) Oral 08/01/2014 Tafinlar (dabrafenib) Oral 08/01/2014 Tecfidera (dimethyl fumarate) Oral 08/01/2014 Xeljanz (tofactinib citrate) Oral 08/01/2014 Xtandi (enzalutamide) Oral 08/01/2014 Xyrem (sodium oxybate) Oral 08/01/2014 Zydelig (idelalsib) Oral 07/25/2014 Zykadia (ceritinab) Oral 05/01/2014 Specialty Drugs Requiring Precertification 7 APPENDIX C HMSA Medical Policies for drugs requiring precertification (click on drug name to link to specific policy): Alimta (Pemetrexed) Avastin (Bevacizumab) Biological Agents for the Treatment of Plaque Psoriasis Botolinum Toxins (BOTOX, DYSPORT, MYOBLOC and XEOMIN) Direct Acting Antiviral Medications for Treatment of Hepatitis C Erbitux (Cetuximab) Forteo (Teriparatide) Growth Hormone Therapy Immune Globulin Therapy Low-Molecular-Weight Heparin Lupron (Leuprolide Acetate) and Supprelin LA (Histrelin Acetate) Subcutaneous Implant Off-Label Drug Use Policy Provigil (Modafinil) and Nuvigil (Armodafinil) Pulmonary Hypertension Drugs Remicade (Infliximab) Synagis (Palivizumab) Vectibix (Panitumumab) Velcade (Bortezomib) Xolair (Omalizumab) Specialty Drugs Requiring Precertification 8 Zevalin (Ibritumomab tiuxetan) Appendix D CVS Medical Policies for drugs requiring precertification (click on this link to access all drug polices and applicable line of business): Adcirca (Tadalafil) Affinitor (Everolimus) Ampyra (Dalfampridine) Bosulif (Bosutinib) Cayston (Aztreonam Inhalation) Copegus (Ribavirin) Cystagon (Cysteamine Bitartrate) Enbrel (Etanercept) Erivedge (Vismodegib) Exjade (Deferasirox) Forteo (Teriparatide) Genotropin (Somatropin [rDNA origin]) Gilenya (Fingolimod) Gleevec (Imatinib Mesylate) Humatrope (Somatropin
Load more

Recommended publications
  • Drug Consumption in 2017 - 2020
    Page 1 Drug consumption in 2017 - 2020 2020 2019 2018 2017 DDD/ DDD/ DDD/ DDD/ 1000 inhab./ Hospital 1000 inhab./ Hospital 1000 inhab./ Hospital 1000 inhab./ Hospital ATC code Subgroup or chemical substance day % day % day % day % A ALIMENTARY TRACT AND METABOLISM 322,79 3 312,53 4 303,08 4 298,95 4 A01 STOMATOLOGICAL PREPARATIONS 14,28 4 12,82 4 10,77 6 10,46 7 A01A STOMATOLOGICAL PREPARATIONS 14,28 4 12,82 4 10,77 6 10,46 7 A01AA Caries prophylactic agents 11,90 3 10,48 4 8,42 5 8,45 7 A01AA01 sodium fluoride 11,90 3 10,48 4 8,42 5 8,45 7 A01AA03 olaflur 0,00 - 0,00 - 0,00 - 0,00 - A01AB Antiinfectives for local oral treatment 2,36 8 2,31 7 2,31 7 2,02 7 A01AB03 chlorhexidine 2,02 6 2,10 7 2,09 7 1,78 7 A01AB11 various 0,33 21 0,21 0 0,22 0 0,24 0 A01AD Other agents for local oral treatment 0,02 0 0,03 0 0,04 0 - - A01AD02 benzydamine 0,02 0 0,03 0 0,04 0 - - A02 DRUGS FOR ACID RELATED DISORDERS 73,05 3 71,13 3 69,32 3 68,35 3 A02A ANTACIDS 2,23 1 2,22 1 2,20 1 2,30 1 A02AA Magnesium compounds 0,07 22 0,07 22 0,08 22 0,10 19 A02AA04 magnesium hydroxide 0,07 22 0,07 22 0,08 22 0,10 19 A02AD Combinations and complexes of aluminium, 2,17 0 2,15 0 2,12 0 2,20 0 calcium and magnesium compounds A02AD01 ordinary salt combinations 2,17 0 2,15 0 2,12 0 2,20 0 A02B DRUGS FOR PEPTIC ULCER AND 70,82 3 68,91 3 67,12 3 66,05 4 GASTRO-OESOPHAGEAL REFLUX DISEASE (GORD) A02BA H2-receptor antagonists 0,17 7 0,74 4 1,10 4 1,11 5 A02BA02 ranitidine 0,00 1 0,63 3 0,99 3 0,99 4 A02BA03 famotidine 0,16 7 0,11 8 0,11 10 0,12 9 A02BB Prostaglandins 0,04 62
    [Show full text]
  • Horizon Therapeutics Public Annual Report 2020
    Horizon Therapeutics Public Annual Report 2020 Form 10-K (NASDAQ:HZNP) Published: February 26th, 2020 PDF generated by stocklight.com octb inte UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2019 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-35238 HORIZON THERAPEUTICS PUBLIC LIMITED COMPANY (Exact name of Registrant as specified in its charter) Ireland Not Applicable (State or other jurisdiction of (I.R.S. Employer incorporation or organization) Identification No.) Connaught House, 1st Floor 1 Burlington Road, Dublin 4, D04 C5Y6, Ireland Not Applicable (Address of principal executive offices) (Zip Code) 011 353 1 772 2100 (Registrant’s telephone number, including area code) Securities registered pursuant to Section 12(b) of the Act: Title of Each Class Trading Symbol Name of Each Exchange on Which Registered Ordinary shares, nominal value $0.0001 per share HZNP The Nasdaq Global Select Market Securities registered pursuant to Section 12(g) of the Act: None Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Yes ☒ No ☐. Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act. Yes ☐ No ☒. Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.
    [Show full text]
  • Transaction Drug 1St (DIN) 2Nd (PIN) 3Rd (PIN) 4Th (PIN) 5Th (PIN) 6Th
    Transaction Drug 1st (DIN) 2nd (PIN) 3rd (PIN) 4th (PIN) 5th (PIN) 6th (PIN) 7th (PIN) 8th (PIN) 9th (PIN) 10th (PIN) 11th (PIN) 12th (PIN) 13th (PIN) Alectinib (Alecensaro®) 02458136 00904400 − − − − − − − − − − − 150 mg capsule Alemtuzumab (LemtradaTM) 02418320 00904161 00904162 00904163 00904164 00904165 00904166 00904167 − − − − − 12 mg / 1.2 mL single-use vial Asfotase alfa (Strensiq®) 02444615 00904483 00904484 00904485 − − − − − − − − − 18 mg / 0.45 mL single-use vial Asfotase alfa (Strensiq®) 02444623 00904486 00904487 00904488 00904489 00904490 − − − − − − − 28 mg / 0.7 mL single-use vial Asfotase alfa (Strensiq®) 02444631 00904491 00904492 00904493 − − − − − − − − − 40 mg / 1 mL single-use vial Asfotase alfa (Strensiq®) 02444658 00904494 00904495 00904496 00904497 00904498 00904499 00904500 00904501 00904502 00904504 00904505 − 80 mg / 0.8 mL single-use vial Canakinumab (Ilaris®) 150 mg/mL powder for solution 02344939 00904404 00903809 00904410 − − − − − − − − − for injection Canakinumab (Ilaris®) 02460351 00904405 00904411 00904412 − − − − − − − − − 150 mg/mL solution for injection Ceftolozane / Tazobactam 02446901 00904433 − − − − − − − − − − − (Zerbaxa®) 1 g / 0.5 g vial Cerliponase Alfa (Brineura®) 150 mg / 5 mL solution for 02484013 00904634 00904635 00904636 − − − − − − − − − intracerebroventricular infusion Cladribine (MavencladTM) 02470179 00904524 00904525 00904526 00904642 − − − − − − − − 10 mg tablet Cysteamine (ProcysbiTM) 02464713 00904354 00904355 − − − − − − − − − − 75 mg delayed-release capsule Daclastavir (DaklinzaTM)
    [Show full text]
  • NTSAD Web Page on Miglustat Fran Platt Substrate Reduction Therapy
    NTSAD Web Page on Miglustat Fran Platt Substrate Reduction Therapy for LSDs Background Several lysosomal storage diseases (LSDs) involve the storage of fatty molecules within cells of the body that are called sphingolipids (1). This is because an enzyme that normally works to break these molecules down in the lysosome, the waste disposal/recycling center of our cells, does not work properly (2, 3). Some sphingolipids are modified by the cells of our bodies by adding sugars, creating a family of specialized sphingolipids called glycosphingolipids (GSLs) (1). For example, in Gaucher disease a glycosphingolipid called glucosylceramide is not broken down and is stored, whereas in Tay-Sachs and Sandhoff disease it is a glycosphingolipid called GM2 ganglioside that is stored (1). Glycosphingolipids are made in the cells of our bodies by a single metabolic pathway that begins with the addition of a sugar molecule called glucose to a sphingolipid molecule called ceramide (1). The fact that there is only a single major pathway to make most glycosphingolipids offers a potential way of treating these diseases using a small molecule drug (4). How would a drug work? The principle behind this treatment is called substrate reduction therapy (SRT)(4). The idea is to partially block the cells in our body from making glycosphingolipids, specifically stopping them from adding glucose to ceramide, which is the first step in this pathway. This would mean fewer glycosphingolipids are made, so fewer would require breaking down in the lysosome. The aim is to balance the rates of glycosphingolipid manufacture with their impaired rate of breakdown.
    [Show full text]
  • Carbaglu and Ravicti
    PHARMACY COVERAGE GUIDELINES ORIGINAL EFFECTIVE DATE: 7/16/2015 SECTION: DRUGS LAST REVIEW DATE: 2/18/2021 LAST CRITERIA REVISION DATE: 2/13/2020 ARCHIVE DATE: CARBAGLU® (carglumic acid) oral tablet RAVICTI® (glycerol phenylbutyrate) oral liquid Coverage for services, procedures, medical devices and drugs are dependent upon benefit eligibility as outlined in the member's specific benefit plan. This Pharmacy Coverage Guideline must be read in its entirety to determine coverage eligibility, if any. This Pharmacy Coverage Guideline provides information related to coverage determinations only and does not imply that a service or treatment is clinically appropriate or inappropriate. The provider and the member are responsible for all decisions regarding the appropriateness of care. Providers should provide BCBSAZ complete medical rationale when requesting any exceptions to these guidelines. The section identified as “Description” defines or describes a service, procedure, medical device or drug and is in no way intended as a statement of medical necessity and/or coverage. The section identified as “Criteria” defines criteria to determine whether a service, procedure, medical device or drug is considered medically necessary or experimental or investigational. State or federal mandates, e.g., FEP program, may dictate that any drug, device or biological product approved by the U.S. Food and Drug Administration (FDA) may not be considered experimental or investigational and thus the drug, device or biological product may be assessed only on the basis of medical necessity. Pharmacy Coverage Guidelines are subject to change as new information becomes available. For purposes of this Pharmacy Coverage Guideline, the terms "experimental" and "investigational" are considered to be interchangeable.
    [Show full text]
  • Specialty Pharmacy Program Drug List
    Specialty Pharmacy Program Drug List The Specialty Pharmacy Program covers certain drugs commonly referred to as high-cost Specialty Drugs. To receive in- network benefits/coverage for these drugs, these drugs must be dispensed through a select group of contracted specialty pharmacies or your medical provider. Please call the BCBSLA Customer Service number on the back of your member ID card for information about our contracted specialty pharmacies. All specialty drugs listed below are limited to the retail day supply listed in your benefit plan (typically a 30-day supply). As benefits may vary by group and individual plans, the inclusion of a medication on this list does not imply prescription drug coverage. Please refer to your benefit plan for a complete list of benefits, including specific exclusions, limitations and member cost-sharing amounts you are responsible for such as a deductible, copayment and coinsurance. Brand Name Generic Name Drug Classification 8-MOP methoxsalen Psoralen ACTEMRA SC tocilizumab Monoclonal Antibody/Arthritis ACTHAR corticotropin Adrenocortical Insufficiency ACTIMMUNE interferon gamma 1b Interferon ADCIRCA tadalafil Pulmonary Vasodilator ADEMPAS riociguat Pulmonary Vasodilator AFINITOR everolimus Oncology ALECENSA alectinib Oncology ALKERAN (oral) melphalan Oncology ALUNBRIG brigatinib Oncology AMPYRA ER dalfampridine Multiple Sclerosis APTIVUS tipranavir HIV/AIDS APOKYN apomorphine Parkinson's Disease ARCALYST rilonacept Interleukin Blocker/CAPS ATRIPLA efavirenz-emtricitabine-tenofovir HIV/AIDS AUBAGIO
    [Show full text]
  • 2021 Formulary List of Covered Prescription Drugs
    2021 Formulary List of covered prescription drugs This drug list applies to all Individual HMO products and the following Small Group HMO products: Sharp Platinum 90 Performance HMO, Sharp Platinum 90 Performance HMO AI-AN, Sharp Platinum 90 Premier HMO, Sharp Platinum 90 Premier HMO AI-AN, Sharp Gold 80 Performance HMO, Sharp Gold 80 Performance HMO AI-AN, Sharp Gold 80 Premier HMO, Sharp Gold 80 Premier HMO AI-AN, Sharp Silver 70 Performance HMO, Sharp Silver 70 Performance HMO AI-AN, Sharp Silver 70 Premier HMO, Sharp Silver 70 Premier HMO AI-AN, Sharp Silver 73 Performance HMO, Sharp Silver 73 Premier HMO, Sharp Silver 87 Performance HMO, Sharp Silver 87 Premier HMO, Sharp Silver 94 Performance HMO, Sharp Silver 94 Premier HMO, Sharp Bronze 60 Performance HMO, Sharp Bronze 60 Performance HMO AI-AN, Sharp Bronze 60 Premier HDHP HMO, Sharp Bronze 60 Premier HDHP HMO AI-AN, Sharp Minimum Coverage Performance HMO, Sharp $0 Cost Share Performance HMO AI-AN, Sharp $0 Cost Share Premier HMO AI-AN, Sharp Silver 70 Off Exchange Performance HMO, Sharp Silver 70 Off Exchange Premier HMO, Sharp Performance Platinum 90 HMO 0/15 + Child Dental, Sharp Premier Platinum 90 HMO 0/20 + Child Dental, Sharp Performance Gold 80 HMO 350 /25 + Child Dental, Sharp Premier Gold 80 HMO 250/35 + Child Dental, Sharp Performance Silver 70 HMO 2250/50 + Child Dental, Sharp Premier Silver 70 HMO 2250/55 + Child Dental, Sharp Premier Silver 70 HDHP HMO 2500/20% + Child Dental, Sharp Performance Bronze 60 HMO 6300/65 + Child Dental, Sharp Premier Bronze 60 HDHP HMO
    [Show full text]
  • State and Specialty Pharmacy Drug Reimbursement Rates
    State and Specialty Pharmacy Drug Reimbursement The following table lists specialty pharmacy drug reimbursement rates. ForwardHealth defines specialty drugs as drugs requiring comprehensive patient care services, clinical management, and product support services. Drugs that meet ForwardHealth’s definition of specialty drugs will be reimbursed using the following rates. However, these rates do not apply to specialty drugs purchased through the federal 340B Drug Discount Program, which will be reimbursed according to the 340B ingredient cost reimbursement methodology. If ForwardHealth uses State Maximum Allowable Cost (SMAC) reimbursement in the future, the SMAC reimbursement rates will be published in this table. Effective 11/01/2020 EAC* EAC* Label Generic Name - Label - Generic ANEMIA/NEUTROPENIA DRUGS ARANESP DARBEPOETIN ALFA IN POLYSORBAT -1.0% EPOGEN EPOETIN ALFA -1.6% FULPHILA PEGFILGRASTIM-JMDB -1.0% GRANIX TBO-FILGRASTIM -1.0% MIRCERA METHOXY PEG-EPOETIN BETA -0.4% NEULASTA PEGFILGRASTIM -1.0% NEUPOGEN FILGRASTIM -1.0% NIVESTYM FILGRASTIM-AAFI -1.0% PROCRIT EPOETIN ALFA -1.6% RETACRIT EPOETIN ALFA-EPBX -1.0% UDENYCA PEGFILGRASTIM-CBQV -1.0% ZARXIO FILGRASTIM-SNDZ -1.0% ZIEXTENZO PEGFILGRASTIM-BMEZ -1.0% ANTICOAGULANT DRUGS ARIXTRA FONDAPARINUX SODIUM -3.0% -50.0% FONDAPARINUX SODIUM FONDAPARINUX SODIUM -50.0% FRAGMIN DALTEPARIN SODIUM,PORCINE -0.4% THROMBATE III ANTITHROMBIN III (PLASMA DER) -0.4% ANTI-INFECTIVE DRUGS ABELCET AMPHOTERICIN B LIPID COMPLEX -0.4% AMBISOME AMPHOTERICIN B LIPOSOME -0.4% ANCOBON FLUCYTOSINE -0.4% -1.0%
    [Show full text]
  • DTF Prior Authorization Drug List
    DTF Prior Authorization Drug List The following is a list of the prescribed drugs included in your prior authorization program and is comprehensive as of the date of publication. Express Scripts Canada® makes every effort to ensure this list is updated regularly. Please note that prior authorization applies to the brand drug and its generic alternatives (if available). As of July 23, 2020 Drug Chemical Ingredient ABSTRAL fentanyl ACTEMRA tocilizumab ADCIRCA tadalafil ADEMPAS riociguat AFINITOR everolimus AIMOVIG erenumab AJOVY fremanezumab ALECENSARO alectinib ALUNBRIG brigatinib ARZERRA ofatumumab AUBAGIO teriflunomide AVASTIN bevacizumab AVSOLA infliximab BALVERSA erdafitinib BANZEL rufinamide BAVENCIO avelumab BENLYSTA belimumab BESPONSA inotuzumab ozogamicin BEOVU brolucizumab BOSULIF bosutinib BOTOX onabotulinumtoxinA BRENZYS etanercept BUDESONIDE budesonide CABLIVI caplacizumab CABOMETYX cabozantinib CALQUENCE acalabrutinib CAPRELSA vandetanib CARBAGLU carglumic acid CERDELGA eliglustat CIMZIA certolizumab CINQAIR reslizumab COSENTYX secukinumab COTELLIC cobimetinib CRESEMBA isavuconazole 1 © Express Scripts Canada. All rights reserved. CRYSVITA burosumab CUVPOSA glycopyrrolate CYRAMZA ramucirumab CYSTADROPS cysteamine DAKLINZA daclatasvir DAURISMO glasdegib DEMYLOCAN decitabine DIACOMIT stiripentol DUODOPA levodopa/carbidopa DUPIXENT dupilumab DYSPORT THERAPEUTIC abobotulinumtoxinA EGRIFTA tesamorelin EMGALITY galcanezumab ENBREL etanercept ENTYVIO vedolizumab EPCLUSA sofosbuvir/velpatasvir ERELZI etanercept ERIVEDGE vismodegib
    [Show full text]
  • Public Summary of Opinion on Orphan Designation Sodium Benzoate, Sodium Phenylacetate for the Treatment of Citrullinaemia Type 1
    2 August 2019 EMADOC-628903358-941 Public summary of opinion on orphan designation Sodium benzoate, sodium phenylacetate for the treatment of citrullinaemia type 1 On 29 May 2019, orphan designation (EU/3/19/2165) was granted by the European Commission to Dipharma B.V., the Netherlands, for sodium benzoate, sodium phenylacetate for the treatment of citrullinaemia type 1. What is citrullinaemia type 1? Citrullinaemia type 1 is one of the inherited disorders known as 'urea-cycle disorders', which cause ammonia to accumulate in the blood. Patients with citrullinaemia type 1 lack argininosuccinate synthase, one of the liver enzymes needed to get rid of excess nitrogen. In the absence of this liver enzyme, excess nitrogen accumulates in the body in the form of ammonia, which can be harmful at high levels, especially to the brain. Symptoms of the disease can appear in the first few days of life or later in life. Early life symptoms include lethargy (lack of energy), vomiting, loss of appetite, seizures (fits) and coma, often leading to death. Citrullinaemia type 1 is a long-term debilitating and life-threatening disease that leads to altered brain function and is associated with poor overall survival. What is the estimated number of patients affected by citrullinaemia type 1? At the time of designation, citrullinaemia type 1 affected less than 0.1 in 10,000 people in the European Union (EU). This was equivalent to a total of fewer than 5,000 people*, and is below the ceiling for orphan designation, which is 5 people in 10,000. This is based on the information provided by the sponsor and the knowledge of the Committee for Orphan Medicinal Products (COMP).
    [Show full text]
  • Drug Consumption at Wholesale Prices in 2017 - 2020
    Page 1 Drug consumption at wholesale prices in 2017 - 2020 2020 2019 2018 2017 Wholesale Hospit. Wholesale Hospit. Wholesale Hospit. Wholesale Hospit. ATC code Subgroup or chemical substance price/1000 € % price/1000 € % price/1000 € % price/1000 € % A ALIMENTARY TRACT AND METABOLISM 321 590 7 309 580 7 300 278 7 295 060 8 A01 STOMATOLOGICAL PREPARATIONS 2 090 9 1 937 7 1 910 7 2 128 8 A01A STOMATOLOGICAL PREPARATIONS 2 090 9 1 937 7 1 910 7 2 128 8 A01AA Caries prophylactic agents 663 8 611 11 619 12 1 042 11 A01AA01 sodium fluoride 610 8 557 12 498 15 787 14 A01AA03 olaflur 53 1 54 1 50 1 48 1 A01AA51 sodium fluoride, combinations - - - - 71 1 206 1 A01AB Antiinfectives for local oral treatment 1 266 10 1 101 6 1 052 6 944 6 A01AB03 chlorhexidine 930 6 885 7 825 7 706 7 A01AB11 various 335 21 216 0 227 0 238 0 A01AB22 doxycycline - - 0 100 0 100 - - A01AC Corticosteroids for local oral treatment 113 1 153 1 135 1 143 1 A01AC01 triamcinolone 113 1 153 1 135 1 143 1 A01AD Other agents for local oral treatment 49 0 72 0 104 0 - - A01AD02 benzydamine 49 0 72 0 104 0 - - A02 DRUGS FOR ACID RELATED DISORDERS 30 885 4 32 677 4 35 102 5 37 644 7 A02A ANTACIDS 3 681 1 3 565 1 3 357 1 3 385 1 A02AA Magnesium compounds 141 22 151 22 172 22 155 19 A02AA04 magnesium hydroxide 141 22 151 22 172 22 155 19 A02AD Combinations and complexes of aluminium, 3 539 0 3 414 0 3 185 0 3 231 0 calcium and magnesium compounds A02AD01 ordinary salt combinations 3 539 0 3 414 0 3 185 0 3 231 0 A02B DRUGS FOR PEPTIC ULCER AND 27 205 5 29 112 4 31 746 5 34 258 8
    [Show full text]
  • Gaucher Disease Agents
    Policy: Gaucher Disease Oral Agents Annual Review Date: Cerdelga (eliglustat) 12/14/2020 miglustat (generic) Last Revised Date: Zavesca (miglustat) 12/14/2020 OVERVIEW Miglustat (Zavesca) is an oral treatment approved for adult patients with mild to moderate type I Gaucher disease if enzyme replacement therapy (Cerezyme, Elelyso, Vpriv) is not a therapeutic option (for example, allergy, hypersensitivity or poor venous access). Miglustat works by inhibiting the enzyme that makes glucosphingolipid. Miglustat’s role in decreasing the rate of glycosphingolipid biosynthesis allows a reduction of the substance to a level which can be cleared by the remaining activity of the naturally occurring defective enzyme. Eliglustat (Cerdelga) is an oral glucosylceramide synthase inhibitor indicated for the long-term treatment of adult patients with Gaucher disease type 1 who are CYP2D6 extensive metabolizers (EMs), intermediate metabolizers (IMs), or poor metabolizers (PMs) as detected by an FDA- cleared test. Gaucher disease is an autosomal recessive lipid storage disorder characterized by a deficiency of glucocerebrosidase. Decreased glucocerebrosidase activity leads to accumulation of glucocerebroside within cell lysosomes in the liver, spleen, bone marrow and bone. Gaucher disease is classified into three clinical types: Type I Gaucher disease, known as non-neuronopathic because there is no central nervous system involvement, is the most common form and occurs at any age, predominantly in individuals of Ashkenazi Jewish descent. The disease involves visceral organs (e.g., liver, spleen), bone marrow and bone. Types II and III Gaucher disease, known as neuronopathic, are very rare forms with neurological involvement in addition to other organs affected by type I Gaucher disease.
    [Show full text]